Amplia Establishes World Class Clinical Advisory Board
Released
Released
Announcement PDF
ABN 16 165 160 841
ASX RELEASE
3 June 2024
AMPLIA ESTABLISHES WORLD CLASS CLINICAL ADVISORY BOARD
HIGHLIGHTS
•
Five experienced oncologists and drug development professionals have been appointed to
Amplia’s Clinical Advisory Board to guide international clinical trial design and development
strategy
Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is
pleased to announce the appointment of five key opinion leaders and clinical oncologists to its Clinical
Advisory Board (CAB).
The CAB will provide expert clinical insight and strategic advice with a particular focus on pancreatic
cancer to Amplia as the Company prepares to undertake clinical trials in the United States.
The CAB will be chaired by Amplia’s long-standing clinical advisor, Dr Jose Iglesias, who has over 30
years’ experience in clinical development of new oncology drugs. Dr Iglesias, who was responsible for
the Phase 3 development of Abraxane® in pancreatic cancer, has commented “I am excited to be
working with Amplia to advance their clinical trial program in pancreatic cancer. Narmafotinib, is a
promising new drug for a devastating and poorly managed disease, greatly in need of new treatment
options.”
Joining Dr Iglesias on the Clinical Advisory Board are leading experts in oncology and drug
development, Dr Jordan Berlin, (Vanderbilt-Ingram Cancer Center, Nashville, USA), Dr Mitesh Borad
(Mayo Clinic, Phoenix, USA), Prof. Nick Pavlakis (North Shore Private Hospital, Sydney), and Dr Jason
Lickliter (Nucleus Network, Melbourne). Further details about each member of the Clinical Advisory
Board can be found on our website www.ampliatx.com.
Amplia CEO and Managing Director Dr Chris Burns commented: “We are delighted to have convened
this distinguished panel of experts. Each member brings a depth of experience that will greatly benefit
both the development of narmafotinib in pancreatic cancer, and the company more broadly as our
clinical strategy matures. This is a significant milestone in the Company’s growth.”
This ASX announcement was approved and authorised for release by the Board of Amplia
Therapeutics.
Level 17, 350 Queen Street, Melbourne VIC 3000
Email info@ampliatx.com
www.ampliatx.com
Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com
About Amplia Therapeutics Limited
Media Contact:
H^CK Director, Haley Chartres
haley@hck.digital
+61 423 139 163
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal
Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the
field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic
and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as
idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia
on Twitter (@ampliatx), Threads (@ampliatx) and LinkedIn.
Share your feedback
Discover